[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
map posts on X about $rgnx, $clsd, $ocul, $eypt the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence stocks XXXX% technology brands XXXX%
Social topic influence $rgnx #3, $clsd #1, $ocul 4.17%, $eypt 4.17%, $abbv 4.17%, phd XXXX%
Top accounts mentioned or mentioned by @clearsidebio @regenxbio @aao2025 @biocrystpharma @blco @bauschlomb @clsd @abbvie @jeremyfalmouth
Top assets mentioned AbbVie Inc (ABBV)
Top posts by engagements in the last XX hours
"$RGNX $OCUL $EYPT $CLSD ASRS survey shows Retina Specialists are most excited about gene therapy for future treatment of Wet AMD.only XX% for TKIs. Don't shoot the messenger this is what the community of Retina Specialists are saying"
X Link @Bio_Scout 2025-08-08T15:02Z XXX followers, 2175 engagements
"$RGNX @REGENXBIO @AAO2025 $ABBV $CLSD @clearsidebio LATE BREAKING ABSTRACT AT AAO NEXT WEEK for RGNX: Suprachoroidal Surabgene Lomparvovec (Sura-vec ABBV-RGX-314): First Time 2-Year Results in Non-Proliferative Diabetic Retinopathy Charles C Wykoff MD"
X Link @Bio_Scout 2025-10-08T16:47Z XXX followers, XXX engagements
"$RGNX @REGENXBIO Dr. Khanani patient is 5+ years going strong on Regenxbio gene therapy: "My journey with sura-vec (formerly RGX-314) began during the Phase 1/2 trial where my enrolled patient remains injection-free to this day following a single dose.""
X Link @Bio_Scout 2025-10-08T15:22Z XXX followers, XXX engagements
"$CLSD $RGNX @clearsidebio @REGENXBIO Late Breaking Abstract for the AAO conference Oct. 17-20th Suprachoroidal Surabgene Lomparvovec (Sura-vec ABBV-RGX-314): First Time 2-Year Results in Non-Proliferative Diabetic Retinopathy Dr. Wykoff MD PhD"
X Link @Bio_Scout 2025-08-29T15:25Z XXX followers, XXX engagements